



## Non-coding RNAs and Epigenetic Alterations in Metal-Induced Carcinogenesis

Guest Editors:

**Dr. Ling-Zhi Liu**

Department of Medical Oncology,  
Sidney Kimmel Cancer Center,  
Thomas Jefferson University,  
Philadelphia, PA 19107, USA

**Prof. Dr. Binghua Jiang**

Department of Pathology,  
Anatomy and Cell Biology, Sidney  
Kimmel Cancer Center, Thomas  
Jefferson University,  
Philadelphia, PA 19107, USA

Deadline for manuscript  
submissions:

**closed (30 June 2023)**

### Message from the Guest Editors

Metals such as hexavalent chromium (Cr(VI)), arsenic, cadmium, and nickel are environmental carcinogens and long-term exposure to these metals is associated with the development of various types of cancer. Non-coding RNAs and epigenetic alterations have recently been demonstrated to be important in metal-induced malignant transformation, angiogenesis, and cancer development. Non-coding RNAs (ncRNAs)—especially micro-RNAs (miRNAs) and long non-coding RNAs (lncRNAs)—have been intensively investigated regarding their roles in cancer development and drug resistance. ncRNAs play important roles in metal-induced carcinogenesis and angiogenesis. This Special Issue will focus on new research findings in elucidating roles and mechanisms of ncRNAs in regulating carcinogenesis. Epigenetic regulations such as DNA methylation, RNA methylation, and histone modifications are other networks mediating carcinogenesis and cancer development. A better understanding of the complex networks of ncRNAs and epigenetic regulations would provide the opportunity to identify new biomarkers and to design new options to prevent metal-induced carcinogenesis in the future.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)